MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)

MDS-482 Impact of magrolimab in combination with azacitidine on red blood cells (RBCs) in patients with higher-risk myelodysplastic syndromes (HR MDS)

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Chen, J, Johnson, L, McKenna, K, Choi, T, Duan, J, Feng, D, Tsai, J, Garcia-Martin, N, Sompalli, K, Maute, R, Vyas, P, Majeti, R, Takimoto, C, Liu, J, Ramsingh, G, Chao, M, Volkmer, J-P, Weissman, I
التنسيق: Conference item
اللغة:English
منشور في: Elsevier 2022

مواد مشابهة

مواد مشابهة